patents news from FierceBiotech
News
'Pharma postman' Langer wins €800,000 tech prize
The prolific Harvard/MIT scientist Robert Langer, whose ideas have spawned a string of biotech start-ups, has won the 800,000-euro Millennium Technology Prize. Langer has been credited with creating Read more...
GSK outlines plans to become more ‘biotech-like’
Biotech is in. At least, that's the message from GlaxoSmithKline's Patrick Vallance, the pharma giant's head Read more...
Bayer, J&J tout rivaroxaban data
In a head-to-head study against Sanofi's Lovenox, Bayer and J&J's oral anti-clotting drug rivaroxaban proved superior in preventing venous blood clots in patients who underwent total knee Read more...
India eyes R&D opportunities
India-based drugs have made a name for themselves as makers of copycat drugs. When a developer's lucrative drug goes off-patent, Indian companies are guaranteed to swoop in and make a less-expensive Read more...
Eisai drug flunks Parkinson's trial
Eisai's has halted development of Perampanel (E2007) for Parkinson's after the drug failed a late-stage trial. Compared with placebo, E2007 didn't show a significant difference in the primary Read more...
Safety, efficacy problems sink Takeda drug
Japan's Takeda has walked away from development of its once-promising cholesterol drug TAK-475. The first sign of Read more...
Boehringer wins approval in anti-clotting drug race
Boehringer Ingelheim has stolen a march on arch rival Bayer, winning European marketing approval for a new anti-clotting agent--Read more...
Follow-on legislation follows a twisted path in DC
BIO is toasting proposed new legislation that would provide more than 14 years of patent protection on a biologic. Needless to say, the generics crowd is just a tad disappointed by the bill, saying Read more...
Astellas faces delay gaining crucial Advagraf approval
Astellas' hopes for a quick U.S. approval for Advagraf--a follow-up, new and improved version of the kidney transplant drug Prograf--have run into a serious obstacle. The drug company says that the Read more...
Teva plans aggressive move into biogenerics
Anyone looking for some real insight into Teva's growth strategy should spend some time with a new Globes article that digs in deep. Shlomo Yanai, who stepped in as CEO a year ago, plans to double Read more...
Get more patents coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets